Get 40% Off
These stocks are up over 10% post earnings. Did you spot the buying opportunity? Our AI did.Read how

CVS Health's forecast points to more pain at long-term care business

Published 02/20/2019, 08:38 AM
© Reuters. FILE PHOTO: A logo of CVS Health is displayed on a monitor above the floor of the New York Stock Exchange shortly after the opening bell in New York

(Reuters) - CVS Health Corp (NYSE:CVS) blamed weakness in its long-term healthcare business for a shortfall in its full-year profit forecast, indicating more troubles at the unit it bought about four years ago.

The company's shares fell 7 percent as it also revealed a $2.2 billion goodwill impairment charge related to the business, which houses the Omnicare unit, in the fourth quarter, taking the total charges at the unit to more than $6 billion in the past year.

The Omnicare business, which the company bought for about $10 billion in 2015, provides prescription drugs to nursing homes and other long-term care centers. It has been hit by lower occupancy rates in skilled nursing facilities and reimbursement pressures in the past few quarters.

"The long-term care business has continued to experience industry wide challenges that have impacted our ability to grow the business at the rate that was originally estimated when the company acquired Omnicare," the company said in a statement.

CVS said the unit's final budget for 2019 showed a significant deterioration in its forecasts for 2019, resulting in further updates to its long-term forecast beyond 2019.

"We are taking comprehensive actions to move past them," Chief Executive Officer Larry Menlo said.

The company, which bought health insurer Aetna (NYSE:AET) last year, forecast full-year 2019 adjusted profit of $6.68 per share to $6.88 per share, while analysts on average currently expect $7.41 per share, according to IBES data from Refinitiv.

Evercore ISI analysts said the main issues with the company appeared to be long-term care challenges, pharmacy reimbursement pressure, lower drug price rise and questions around rebates.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

For the fourth quarter, CVS Health earned $2.14 per share excluding items, beating the average estimate of $2.05 per share.

Same-store sales at the company's pharmacies that sell prescription drugs rose 7.4 percent in the quarter, compared with an expected 6.1 percent rise forecast by analysts.

The company booked a net loss of $419 million in the fourth quarter ended Dec. 31, compared with a net income of $3.29 billion, a year earlier when it benefited from changes to U.S. tax laws.

Revenue rose to $54.42 billion in the quarter from $48.39 billion a year earlier.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.